Flaws of E-Prescribing

Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, discusses some flaws of e-prescribing.

Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, discusses some flaws of e-prescribing.

This video was recorded at the 2015 NCPA Annual Convention.

Related Videos
Credit: wladimir1804 - stock.adobe.com
Women buying contraceptive pills in the pharmacy | Image credit: Antonioguillem - stock.adobe.com
Healthcare technology | Image credit: ipopba | stock.adobe.com
Medical science laboratory | Image credit: alphaspirit - stock.adobe.com
Gastroenterologist using digital x-ray of human intestine holographic scan projection 3D rendering | Image Credit: sdecoret - stock.adobe.com
Supreme Court | Image credit: steheap - stock.adobe.com
Pharmacists talking with a nurse | Image credit: Jacob Lund - stock.adobe.com
Related Content

FDA Grants Fast Track Designation to Milvexian for Multiple Prospective Cardiovascular Indications

June 6th 2023

Pharmacy Focus: Student Edition - Creatives in Pharmacy

May 30th 2023

Why Choose a Career in Community Pharmacy?

June 5th 2023

BONUS: American Association of Pharmacy Technicians Convention 2023

May 24th 2023

Clinical Overview: Dapagliflozin for Patients with Heart Failure, Reduced Ejection Fraction and Preserved Ejection Fraction

June 2nd 2023

Five-Year Data Show Superiority of Upadacitinib to Adalimumab Treating Rheumatoid Arthritis

June 2nd 2023

FDA Grants Fast Track Designation to Milvexian for Multiple Prospective Cardiovascular Indications

June 6th 2023

Pharmacy Focus: Student Edition - Creatives in Pharmacy

May 30th 2023

Why Choose a Career in Community Pharmacy?

June 5th 2023

BONUS: American Association of Pharmacy Technicians Convention 2023

May 24th 2023

Clinical Overview: Dapagliflozin for Patients with Heart Failure, Reduced Ejection Fraction and Preserved Ejection Fraction

June 2nd 2023

Five-Year Data Show Superiority of Upadacitinib to Adalimumab Treating Rheumatoid Arthritis

June 2nd 2023

FDA Grants Fast Track Designation to Milvexian for Multiple Prospective Cardiovascular Indications

June 6th 2023

Pharmacy Focus: Student Edition - Creatives in Pharmacy

May 30th 2023

Why Choose a Career in Community Pharmacy?

June 5th 2023

BONUS: American Association of Pharmacy Technicians Convention 2023

May 24th 2023

Clinical Overview: Dapagliflozin for Patients with Heart Failure, Reduced Ejection Fraction and Preserved Ejection Fraction

June 2nd 2023

Five-Year Data Show Superiority of Upadacitinib to Adalimumab Treating Rheumatoid Arthritis

June 2nd 2023
© 2023 MJH Life Sciences

All rights reserved.